GlassScriptPhysician profile
Olivia Nastovski
NPI 1740866896
$2,961.78
in general payments reported to CMS, 2019-2025
24 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $521 · 2023: $344 · 2024: $555 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $585.75 | 2024-2025 | Nayzilam, Briviact, Fintepla |
| Boston Scientific Corporation | $381.88 | 2022-2023 | |
| Abbvie INC. | $253.98 | 2024-2025 | |
| Axsome Therapeutics, INC. | $217.08 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $204.99 | 2022 | |
| Celgene Corporation | $159.15 | 2021-2025 | Zeposia |
| Lundbeck LLC | $148.98 | 2025 | Vyepti |
| Tg Therapeutics, INC. | $125.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $116.72 | 2021 | |
| Pfizer INC. | $103.99 | 2024-2025 | |
| Argenx US, INC. | $102.12 | 2024-2025 | Vyvgart Hytrulo |
| Neurelis, INC. | $74.86 | 2023-2025 | Valtoco |
| Lilly USA, LLC | $74.25 | 2021-2025 | Kisunla |
| Novartis Pharmaceuticals Corporation | $61.73 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $57.34 | 2024 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $56.44 | 2024 | Nuplazid |
| Eisai INC. | $53.50 | 2025 | |
| Tanabe Pharma America, INC. | $51.08 | 2025 | Radicava |
| Sk Life Science, INC. | $31.80 | 2023 | |
| Genentech USA, INC. | $28.90 | 2025 | Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $20.41 | 2025 | Ponvory |
| Biohaven Pharmaceutical Holding Company LTD. | $20.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.99 | 2025 | Hyqvia |
| Horizon Therapeutics Plc | $15.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Nastovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.